Alcon's $200M RxSight partnership aims to recapture IOL market share with adjustable presbyopic lenses. RxSight gets 30% ...
Medical Device Network on MSN
Alcon spends up to $200M to co-develop customisable cataract lenses with RxSight
The companies will combine their expertise to develop a ‘tuneable’ presbyopia-correcting intraocular lens (PCIOL) for ...
Alcon (NYSE:ALC) and RxSight (Nasdaq:RXST) announced that they entered into a non-exclusive intraocular lens (IOL) ...
ALC is developing adjustable presbyopia-correcting lenses that pair advanced optics with post-surgery light adjustment.
Non-exclusive license agreement for the development and commercialization of novel post-operative light adjustable PCIOL technologies ...
“Alcon is proud to be the title sponsor of SECO 2020 and welcomes the opportunity to connect with Eye Care Professionals (ECPs) while providing hands-on access to our latest, innovative eye care ...
Alcon innovations featured in more than 75 abstracts across cataract, refractive, visualization and ocular health1 Clinical data presentations and sponsored symposia to highlight the efficacy of Alcon ...
Alcon and RxSight, Inc have announced a non-exclusive collaboration to jointly develop adjustable presbyopia-correcting ...
GENEVA & DURHAM, N.C.--(BUSINESS WIRE)-- Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, and Aerie Pharmaceuticals, Inc. (NASDAQ: AERI, “Aerie”), a ...
Acquisition of ALLY Robotic Cataract Laser Systems strengthens Alcon’s cataract equipment and technology portfolio Next generation technology will be expanded globally, improving the efficiency of ...
GENEVA--(BUSINESS WIRE)--Alcon (SIX/NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, today released its inaugural Corporate Responsibility (CR) report. The CR ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results